Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors

Inclusion Criteria

• •1. The subject or their legally authorized representative (LAR) is capable of providing a signed and dated informed consent form (ICF);
• •2. Willing and able to comply with all study procedures and cooperate throughout the entire duration of the study;
• •3. Adult patients or healthy volunteers, aged 18 years or older, male or female;
• •4. Patients with clinically suspected or confirmed malignancies (supported by evidence such as relevant serum tumor markers, imaging modalities including ultrasound, CT, and MRI, or histopathological examinations) who are in good general condition;
• •5. Women of childbearing potential (WOCBP) must have used effective contraception for at least one month prior to screening and agree to continue contraceptive use throughout the study period and for a specified duration following study completion;